Kefir exhibits anti-proliferative and pro-apoptotic effects on colon adenocarcinoma cells with no significant effects on cell migration and invasion

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2117-2127

  Khoury, Nathalie ^a   El Hayek, Stephany ^a   Tarras, Omayr ^a   El Sabban, Marwan ^b   El Sibai, Mirvat ^a   Rizk, Sandra ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Apoptosis; Cell invasion; Cell motility; Colorectal cancer; Kefir

Indexed keywords

GELATINASE A; GELATINASE B; KEFIR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR PROTEIN;

ADENOCARCINOMA CELL LINE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CACO 2 CELL LINE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA CONTENT; DRUG MECHANISM; FLOW CYTOMETRY; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WOUND HEALING; ADENOCARCINOMA; BIOSYNTHESIS; CELL CYCLE; CELL MOTION; COLONIC NEOPLASMS; DAIRY PRODUCT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR INVASION;

ADENOCARCINOMA; APOPTOSIS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; CULTURED MILK PRODUCTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS;

EID: 84907212867     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2635     Document Type: Article

References (42)

1. Adriana P and Socaciu C: Probiotic activity of mixed cultures of kefir's lactobacilli and non-lactose fermenting yeasts. Agric 65: 329-334, 2008.
2. Farnworth ER: Kefir -a complex probiotic. Food Sci Technol Bull 2: 1-17, 2005.
3. Angulo L, Lopez E and Lema C: Microflora present in kefir grains of the Galician region (north-west of Spain). J Dairy Res 60: 263-267, 1993.
4. Lopitz-O tsoa F, Rementeria A, Elguezabal N and Garaizar J: Kefir: A symbiotic yeasts-bacteria community with alleged healthy capabilities. Rev Iberoam Micol 23: 67-74, 2006.
5. Simova E, Simov Z, Beshkova D, Frengova G, Dimitrov Z and Spasov Z: Amino acid profiles of lactic acid bacteria, isolated from kefir grains and kefir starter made from them. Int J Food Microbiol 107: 112-123, 2006.
6. Liu JR , Wang SY, Lin YY and Lin CW: Antitumor activity of milk kefir and soy milk kefir in tumor-bearing mice. Nutr Cancer 44: 182-187, 2002.
7. Vinderola G, Perdigón G, Duarte J, Farnworth E and Matar C: Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Cytokine 36: 254-260, 2006.
8. Hertzler SR and Clancy SM: Kefir improves lactose digestion and tolerance in adults with lactose maldigestion. J Am Diet Assoc 103: 582-587, 2003.
9. Liu JR , Wang SY, Chen MJ, Chen HL, Yueh PY and Lin CW: Hypocholesterolaemic effects of milk-kefir and soyamilk-kefir in cholesterol-fed hamsters. Br J Nutr 95: 939-946, 2006.
10. Preidis GA , Hill C, Guerrant RL , Ramakrishna BS, Tannock GW and Versalovic J: Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology 140: 8-14, 2011.
11. Chen C, Chan HM and Kubow S: Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells. J Med Food 10: 416-422, 2007.
12. Rodrigues KL, Caputo LR , Carvalho JC , Evangelista J and Schneedorf JM: Antimicrobial and healing activity of kefir and kefiran extract. Int J Antimicrob Agents 25: 404-408, 2005.
13. Shiomi M, Sasaki K, Murofushi M and Aibara K: Antitumor activity in mice of orally administered polysaccharide from Kefir grain. Jpn J Med Sci Biol 35: 75-80, 1982.
14. Murofushi M, Shiomi M and Aibara K: Effect of orally administered polysaccharide from kefir grain on delayed-type hypersensitivity and tumor growth in mice. Jpn J Med Sci Biol 36: 49-53, 1983.
15. Murofushi M, Mizuguchi J, Aibara K and Matuhasi T: Immunopotentiative effect of a polysaccharide from kefir grain, KGF-C , administered orally in mice. Immunopharmacology 12: 29-35, 1986.
16. Furukawa N, Matsuoka A and Yamanaka Y: Effects of orally administered yoghurt and kefir on tumor growth in mice. J Jpn Soc Nutr Food Sci 43: 450-453, 1990.
17. Kubo M, Odani T, Nakamura S, Tokumaru S and Matsuda H: Pharmacological study on kefir -a fermented milk product in Caucasus. ?. On antitumor activity (1). Yakugaku Zasshi 112: 489-495, 1992 (In Japanese).
18. Rizk S, Maalouf K and Baydoun E: The antiproliferative effect of kefir cell-free fraction on HuT-102 malignant T lymphocytes. Clin Lymphoma Myeloma (Suppl 3): S198-S203, 2009.
19. Maalouf K, Baydoun E and Rizk S: Kefir induces cell-cycle arrest and apoptosis in HTLV-1-negative malignant T-lymphocytes. Cancer Manag Res 3: 39-47, 2011.
20. Furukawa N , M atsuoka A , Takahashi T a nd Yamanaka Y: Anti-metastatic effect of kefir grain components on Lewis lung carcinoma and highly metastatic B16 melanoma in mice. J Agric Sci Tokyo Nogyo Daigaku 45: 62-70, 2000.
21. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. Cancer J Clin 2013, 63: 11-30.
22. Hamilton SR: The molecular genetics of colorectal neoplasia. Gastroenterology 105: 3-7, 1993.
23. Hoff G, Foerster A, Vatn MH, Sauar J and Larsen S: Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection. Scand J Gastroenterol 21: 853-862, 1986.
24. Wolpin BM and Mayer RJ : Systemic treatment of colorectal cancer. Gastroenterology 134: 1296-1310, 2008.
25. Messersmith WA and Hidalgo M: Panitumumab, a monoclonal anti-epidermal growth factor receptor antibody in colorectal cancer: Another one or the one? Clin Cancer Res 13: 4664-4666, 2007.
26. Arteaga C: Targeting HER 1/EGFR : A molecular approach to cancer therapy. Semin Oncol (3 Supp 7): S3-S14, 2003.
27. Rodriguez-Bigas MA, Lin EH and Crane CH: Stage ? colorectal cancer. In: Holland-Frei Cancer Medicine. Kufe DW, Pollock RE , Weichselbaum RR , Bast RC , Gansler TS, Holland JF and Frei E (eds). Vol 2. 6th edition. Hamilton, ON, 2003.
28. Hassan MS, Ansari J, Spooner D and Hussain SA: Chemotherapy for breast cancer (Review). Oncol Rep 24: 1121-1131, 2010.
29. Palmer TD, Ashby WJ, Lewis JD and Zijlstra A: Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev 63: 568-581, 2011.
30. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, et al: Epidermal growth factor receptor variant ? mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103: 7817-7822, 2006.
31. Liu C, Woo A and Tsao MS: Expression of transforming growth factor-alpha in primary human colon and lung carcinomas. Br J Cancer 62: 425-429, 1990.
32. Sasaki T, Nakamura T, Rebhun RB, Cheng H, Hale KS, Tsan RZ, Fidler IJ and Langley RR: Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am J Pathol 173: 205-216, 2008.
33. Ueda M, Fujii H, Yoshizawa K, Terai Y, Kumagai K, Ueki K and Ueki M: Effects of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells. Invasion Metastasis 18: 176-183, 1998.
34. Hölting T, Siperstein AE , Clark OH and Duh QY: Epidermal growth factor (EGF)-and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 132: 229-235, 1995.
35. Massagué J: TGF β signalling in context. Nat Rev Mol Cell Biol 13: 616-630, 2012.
36. Halder SK, Beauchamp RD and Datta PK: A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7: 509-521, 2005.
37. Xiong B, Yuan HY, Hu MB, Zhang F, Wei ZZ , Gong LL and Yang GL: Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. World J Gastroenterol 8: 674-678, 2002.
38. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
39. Ramesh S, Wildey GM and Howe PH: Transforming growth factor beta (TGF beta)-induced apoptosis: The rise and fall of Bim. Cell Cycle 8: 11-17, 2009.
40. Akhurst RJ and Hata A: Targeting the TGF β signalling pathway in disease. Nat Rev Drug Discov 11: 790-811, 2012.
41. Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, Dezube BJ, Hsu FJ, Reiss M and Berzofsky JA: Phase ?/? study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 26 (Suppl 15): S9028, 2008.
42. Fidler IJ : The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.